572 related articles for article (PubMed ID: 17825167)
1. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
[TBL] [Abstract][Full Text] [Related]
2. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
[TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
Schiff E; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann H; Samuel D; Zeuzem S; Villeneuve JP; Arterburn S; Borroto-Esoda K; Brosgart C; Chuck S;
Liver Transpl; 2007 Mar; 13(3):349-60. PubMed ID: 17326221
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
Lo CM; Liu CL; Lau GK; Chan SC; Ng IO; Fan ST
Liver Transpl; 2005 Jul; 11(7):807-813. PubMed ID: 15973721
[TBL] [Abstract][Full Text] [Related]
6. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
[TBL] [Abstract][Full Text] [Related]
7. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Schiff ER; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann HL; Samuel D; Zeuzem S; Lilly L; Rendina M; Villeneuve JP; Lama N; James C; Wulfsohn MS; Namini H; Westland C; Xiong S; Choy GS; Van Doren S; Fry J; Brosgart CL;
Hepatology; 2003 Dec; 38(6):1419-27. PubMed ID: 14647053
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
9. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant.
Wai CT; Prabhakaran K; Wee A; Lee YM; Dan YY; Sutedja DS; Mak K; Isaac J; Lee KH; Lee HL; Da Costa M; Lim SG
Transplant Proc; 2004 Oct; 36(8):2313-4. PubMed ID: 15561234
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
[TBL] [Abstract][Full Text] [Related]
11. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
12. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
Bárcena R; Del Campo S; Moraleda G; Casanovas T; Prieto M; Buti M; Moreno JM; Cuervas V; Fraga E; De la Mata M; Otero A; Delgado M; Loinaz C; Barrios C; Dieguez ML; Mas A; Sousa JM; Herrero JI; Muñoz R; Avilés JF; Gonzalez A; Rueda M
Transplant Proc; 2005 Nov; 37(9):3960-2. PubMed ID: 16386596
[TBL] [Abstract][Full Text] [Related]
13. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.
Caccamo L; Romeo R; Rossi G; Maggioni M; Radice F; Lunghi G; Colombo M; Fassati LR
Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271
[TBL] [Abstract][Full Text] [Related]
14. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
[TBL] [Abstract][Full Text] [Related]
15. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
17. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy.
Kwon HC; Cheong JY; Cho SW; Choi JM; Hong SP; Kim SO; Yoo WD
J Gastroenterol Hepatol; 2009 Jan; 24(1):49-54. PubMed ID: 19196395
[TBL] [Abstract][Full Text] [Related]
18. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
20. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
